UNC CFAR research Findings


Community Voices


Ron Strauss, DMD, PhD


Dr. Ronald P. Strauss is University of North Carolina at Chapel Hill’s Executive Vice Provost and Chief International Officer. Dr. Strauss’s research has focused on the social...

Read more

Madison Hayes


Madison connects the CFAR to communities and community agencies. She actively aids CFAR investigators in translating research results back to the community...

Read more

Danielle Strauss

Outreach Coordinator

Danielle designs and develops the CFAR’s dissemination and communications strategies to foster knowledge-sharing, partnership, and collaboration...

Read more

The last Friday ID conference of the season is: "Ogston's Affection: Translational Approaches to S. aureus Colonization and Disease"

C. Buddy Creech, MD, MPH
Associate Director, Vanderbilt Vaccine Research Program
Associate Professor, Pediatric Infectious Diseases
Vanderbilt University School of Medicine

May 29, 2015
8:30 - 9:30 a.m.
1131 Bioinformatics
UNC Campus

Buddy Creech, MD, MPH, is a native of Chattanooga, Tennessee. He graduated cum laude from Vanderbilt University in Nashville, Tennessee with a B.S. in biology. After attending the University of Tennessee College of Medicine, he joined the pediatric housestaff at Vanderbilt University Medical Center. After internship, residency, and chief residency in pediatrics, Dr. Creech began a pediatric infectious diseases fellowship at Vanderbilt under the mentorship of Dr. Kathryn Edwards.

During fellowship, Dr. Creech studied the clinical and molecular epidemiology of community-associated methicillin-resistant Staphylococcus aureus (MRSA) colonization and disease. He received a Masters in Public Health upon completion of his thesis, Impact of Staphylococcal Vaccination on Nasal Colonization, in which healthcare workers were vaccinated with a candidate S. aureus vaccine to determine potential impact on nasal colonization and, therefore, healthcare-associated transmission. His focus has recently turned to defining the adaptive immune response to invasive S. aureus infections in children and young adults, with a particular emphasis on the multiple two-component exotoxins used by staphylococci to evade host responses. These data will inform intelligent staphylococcal vaccine design and immunotherapeutic product development. His work is funded by the National Institutes of Health (Co-PI, Vaccine and Treatment Evaluation Unit), t he Centers for Disease Control and Prevention (Co-PI, Clinical Immunization Safety Assessment Network), and various industry partners.

In 2007, Dr. Creech was awarded the Young Investigator Award in MRSA Research by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. He is a Fellow in the American Academy of Pediatrics, Fellow of the Pediatric Infectious Diseases Society, and a member of the Vanderbilt University Faculty Senate.

Refreshments will be served!!
... See MoreSee Less

2 days ago

A new HIV medication (GSK 1265744) that will be used for both HIV treatment and HIV prevention is being evaluated in a new study, currently recruiting people who are HIV negative to ensure that the drug is safe for people who are HIV negative and that the drug causes little or no side effects.

This study will last approximately 1.5 years. Participants will receive oral tablets of GSK744 or placebo for 4 weeks, followed by one week without medication. Participants who have little or no side effects with the oral tablets will then be given the medication or placebo via two intra-muscular injections (shot) in the gluteal (butt) muscles at three time points every 12 weeks over a 6 month time period. The injectable form of the drug is long-acting. Participants will have 19 study visits over the course of 81 weeks.

You may be eligible if:
1. You are between the ages of 18-65 years old 2. You are HIV negative 3. You are in good health 4. You are able to swallow pills and are willing to receive intra-muscular injections 5. You are not pregnant, breastfeeding, or planning on becoming pregnant for 2 years.
6. You do not have cardiovascular disease, liver disease, or any skin disease

Participants will be eligible to earn $50 per visit and up to $950 for completing all study visits.

If interested, please reply to hptn_research@med.unc.edu with the following information:
E-mail address
Phone number
Best time to be contacted

This study titled "A Phase IIa Study to Evaluate the Safety and Pharmacokinetics of the Investigational Injectable HIV Integrase inhibitor, GSK1265744, in HIV-uninfected Men and Women” was approved by the UNC Biomedical IRB# 14-1309, initial approval date 7/16/14.
... See MoreSee Less

3 days ago